



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Docket No: Q90288  
Egil JELLUM et al Conf. No.: 7146  
Appln. No.: 10/549,902 Group Art Unit: 1645  
Filed: November 3, 2006 Examiner: Unassigned  
For: ANTI-INFLAMMATORY TREATMENT

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 and 1.98**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicants hereby notify the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of each of the listed documents (except U.S. patents and/or publications; and co-pending non-provisional U.S. applications filed after June 30, 2003) is submitted herewith.

The present Information Disclosure Statement is being filed after three months from the application's filing date, but before the mailing date of the first Office Action on the merits. Therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art

**INFORMATION DISCLOSURE STATEMENT**  
**U.S. Appln. No. 10/549,902**

against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

*Respectfully submitted,*

*Gordon Kit*

*Registration No. 30,764*

**SUGHRUE MION, PLLC**  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

**23373**

CUSTOMER NUMBER

Date: March 15, 2007

Substitute for Form 144b A &amp; B/PTO

Complete if Known

Application Number	U.S. Appln. No. 10/549,902
Confirmation Number	7146
Filing Date	November 3, 2006
First Named Inventor	Egil JELLUM et al
Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	Q90288

MAR 15 2007

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

SEARCHED

1

of

5

Attorney Docket Number

Q90288

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US 5,866,168		02/02/1999	De Lacharriere et al
		US 5,851,556		12/22/1998	Brenton et al
		US 4,141,359		02/27/1979	Jacobsen et al
		US 5,958,462		09/28/1999	McLean
		US 4,363,818		12/14/1982	Gottlieb
		US 5,260,289		11/09/1993	Hyodo et al
		US 4,650,668		03/17/1987	Barron et al
		US 4,756,909		07/12/1988	Revici
		US 3,865,933		02/11/1975	Mudge
		US 5,856,356		01/05/1999	Tsouderos et al
		US 5,716,625		02/10/1998	Hahn et al
		US 4,645,662		02/24/1987	Nakashima et al
		US 4,866,046		09/12/1989	Amer
		US 4,634,589		01/06/1987	Scheller
		US 3,988,434		10/26/1976	Schole et al
		US 4,146,606		03/27/1979	Yamaga et al
		US 6,139,850		10/21/2000	Hahn et al
		US 5,804,203		09/08/1998	Hahn et al

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		WO	97/48371		12/24/1997	Cosmedern Technologies	
		WO	96/01634		01/25/1996	Norbrook Laboratories Limited	
		WO	98/03179		01/29/1998	Alexander Mauskop	
		WO	98/47519		10/29/1998	Fleming & Co., Pharmaceuticals	
		WO	94/09798		05/11/1994	The Bonaparte Company	
		WO	86/03413		06/19/1986	Hadziselimovic	None
		EP	0 575 841		06/12/1993	Vitacain Pharmaceutical Co., Ltd.	
		CA	1 179 267		12/11/1984	Barron et al	
		WO	96/19184		06/27/1996	Cosmederm Technologies	
		EP	0 834 319		04/08/1998	Dr. Kartar Lalvani	

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		Hahn et al, <i>American Society for Dermatologic Surgery Inc.</i> , 25(9):689-694 (1999)	
		Early et al, <i>Health Physics</i> , 69(5):677-693 (1995)	
		Jill Stein, "DG Dispatch - ACAAI: Strontium Suppresses Itching In Allergy Skin Reactions", <i>Doctor's Guide</i> (November 5, 2000)	
		"Cosmederm - 7 <sup>TM</sup> , Product Information (May 25, 2002)	
		"Cosmederm - 7 <sup>TM</sup> , Cosmederm Technology (May 25, 2002)	
		Meunier et al, "Endocrine Care", <i>J. of Clinical Endocrinology &amp; Metabolism</i> , 87(2):2060-2066	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A &amp; B/PTO

Complete if Known

Application Number	U.S. Appln. No. 10/549,902
Confirmation Number	7146
Filing Date	November 3, 2006
First Named Inventor	Egil JELLUM et al
Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	Q90288

MAR 15 2007

## DRAFT INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

2

of 5

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US 6,168,809		02/02/2001	De Lacharriere et al
		US 5,330,746		07/19/1994	Friedman et al
		US 5,855,870		01/05/1999	Fischer
		US 5,851,512		12/22/1998	Fischer
		US 5,188,818		02/23/1993	Merianos et al
		US 5,958,436		09/28/1999	Hahn et al
		US 5,380,530		01/10/1995	Hill
		US 5,234,971		08/10/1993	Imai et al
		US 4,083,965		04/11/1978	Bluhm

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		Zaichik et al, No. 34810z, <i>Chem. Abstracts</i> , 70:62 (1969)	Abstract
		Moya-Hernandez et al, No. 131:266581g, <i>Chem. Abstracts, 1-Pharmacology</i> , 131(20):26 (1999)	Abstract
		Ghandour et al, No. 110:142402w, <i>Chem. Abstracts, 68-Equilibria, Solutions</i> , 110:479 (1989)	Abstract
		Krishnan et al, No. 90:66866b, <i>Chem. Abstracts</i> , 90:56 (1979)	Abstract
		Kaufmann et al, <i>Arch. Pharm.</i> , 278:443-448 (1941)	Abstract
		Kaufmann et al, "Complex Barbituric Acid Compounds", Column 1407, <i>Chem. Abstracts</i> , Vol. 32 (1937)	Abstract
		Perrier, "Strontium Trictrate", Column 11860, <i>Chem. Abstracts</i> , Vol. 61 (May 1964)	Abstract
		Simon, <i>Boll. Soc. Ital. Biol. Sper.</i> , 4:1197-1199 (1929)	Abstract
		Simon, <i>Arch. Farmacol. Sper.</i> , <i>Chem. Abstracts</i> , Column 4472, Vol. 28 (1934)	Abstract
		Yannis, No. 128:97710d, <i>Chem. Abstracts, 1-Pharmacology</i> , 128(9):68 (1998)	Abstract
		Neirinckx, No. 116:241750p, <i>Chem. Abstracts</i> , 116:408 (1992)	Abstract
		Friedman, No. 114:88683f, <i>Chem. Abstracts, 63-Pharmacology</i> , 114:445 (1991)	Abstract
		Surovezhin, No. 741z, <i>Chem. Abstracts, 5-Radiation Biochem.</i> , 73:63 (1970)	Abstract
		Gassmann, <i>Schweiz. Med. Wochschr.</i> , 68:291-292 (1938)	Abstract
		Sankaram, No. 103:105312b, <i>Chem. Abstracts, 34-Amino Acids, Peptides, Proteins</i> , 103:659 (1985)	Abstract
		Peppas et al, <i>Biomaterials</i> , 17(16):1553-1561 (1996)	Abstract
		Lehr, <i>Eur. J. Drug Metab. Pharmacokinet.</i> , 21(2):139-148 (1996)	Abstract
		Joshi, <i>Ocul. Pharmacol.</i> , 10(1):29-45 (1994)	Abstract
		Lehr, <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 11(2-3):119-160 (1994)	Abstract
		Bernkop-Schnurch et al, <i>Adv. Drug Deliv. Rev.</i> , 52(2):127-137 (2001)	Abstract
		Morishita et al, <i>Nippon Rinsho</i> , 59(11):2255-2260 (2001)	Abstract
		Singla et al, <i>J. Pharm. Pharmacol.</i> , 53(8):1047-1067 (2001)	Abstract
		Bures et al, <i>J. Control Release</i> , 72(1-3):25-33 (2001)	Abstract
		Woodley, <i>Clin. Pharmacokinet.</i> , 40(2):77-84 (2001)	Abstract

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<i>Complete if Known</i>	
PAPER MAR 15 2007 1449.16.1 sheet		3	of	5	Application Number U.S. Appln. No. 10/549,902
					Confirmation Number 7146
					Filing Date November 3, 2006
					First Named Inventor Egil JELLUM et al
					Art Unit 1645
					Examiner Name Unassigned
					Attorney Docket Number Q90288

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code <sup>3</sup>	Number <sup>4</sup>		

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			Translation <sup>6</sup>
		Takeuchi et al, <i>Adv. Drug Deliv. Rev.</i> , 47(1):39-54 (2001)			Abstract
		Sakuma et al, <i>Adv. Drug Deliv. Rev.</i> , 47(1):21-37 (2001)			Abstract
		Muller et al, <i>Adv. Drug Deliv. Rev.</i> , 47(1):3-19 (2001)			Abstract
		Ugwoke et al, <i>J. Pharm. Pharmacol.</i> , 53(1):3-21 (2001)			Abstract
		Dostalova et al, <i>Ceska Slov. Farm.</i> , 49(2):55-61 (2000)			Abstract
		Singla et al, <i>Drug Deliv. Ind. Pharm.</i> , 26(9):913-924 (2000)			Abstract
		Aungst, <i>J. Pharma Sci.</i> , 89(4):429-442 (2000)			Abstract
		Huang et al, <i>J. Control. Rel.</i> , 65(1-2):63-71 (2000)			Abstract
		Bernkop-Schnurch, <i>Int. J. Pharm.</i> , 194(1):1-13 (2000)			Abstract
		Hwang et al, <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 15(3):243-284 (1998)			Abstract
		Bernkop-Schnurch, <i>J. Control. Rel.</i> , 52(1-2):1-16 (1998)			Abstract
		Vyas et al, <i>Pharmazie</i> , 52(5):339-345 (1997)			Abstract
		Gwak et al, <i>Arch. Pharm. Res.</i> , 25(3):392-396 (2002)			Abstract
		Karande et al, <i>Pharm. Res.</i> , 19(5):655-660 (2002)			Abstract
		Aguilar et al, <i>BMC Infect. Dis.</i> , 2(1):9 (2002)			Abstract
		Touitou et al, <i>J. Control. Rel.</i> , 80(1-3):1-7 (2002)			Abstract
		Wiechers et al, <i>Drug. Des. Deliv.</i> , 6(2):87-100 (1990)			Abstract
		Willams et al, <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 9(3-4):305-353 (1992)			Abstract
		Hermens, <i>Pharm. Weekbl. Sci.</i> , 14(14A):253-257 (1992)			Abstract
		Berti et al, <i>Mayo Clin. Proc.</i> , 70(6):581-586 (1995)			Abstract
		Bach et al, <i>Eur. J. Pharm. Biopharm.</i> , 46(1):1-13 (1998)			Abstract
		Marjukka Suhonen et al, <i>J. Control Rel.</i> , 59(2):149-161 (1999)			Abstract
		Kanikkannan et al, <i>Curr. Med. Chem.</i> , 7(6):593-608 (2000)			Abstract
		Mastropaoletti et al, <i>J. Med. Chem.</i> , 44(2):269-273 (2001)			Abstract
		Moraes et al, <i>Br. J. Clin. Pharmacol.</i> , 32(4):441-445 (1991)			Abstract
		Moraes et al, <i>Br. J. Clin. Pharmacol.</i> , 31(4):423-427 (1991)			Abstract
		Llobet et al, <i>Res. Commun Chem. Pathol. Pharmacol.</i> , 72(2):243-246 (1991)			Abstract
		Colomina et al, <i>Vet. Hum. Toxicol.</i> , 33(2):121-124 (1991)			Abstract
		Llobet et al, <i>Arch. Environ Contam. Toxicol.</i> , 21(4):612-620 (1991)			Abstract
		Llobet et al, <i>Vet. Hum. Toxicol.</i> , 34(1):7-9 (1992)			Abstract

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	U.S. Appln. No. 10/549,902
<i>MAR 15 2007</i>		Confirmation Number	7146
		Filing Date	November 3, 2006
		First Named Inventor	Egil JELLUM et al
		Art Unit	1645
		Examiner Name	Unassigned
Sheet	4	of	5
		Attorney Docket Number	
		Q90288	

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			

#### NON-PATENT LITERATURE DOCUMENTS

**Examiner Signature** \_\_\_\_\_ **Date Considered** \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.

Substitute for Form 1449 A & B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	U.S. Appln. No. 10/549,902
<i>MAR 15 2007</i>		Confirmation Number	7146
		Filing Date	November 3, 2006
		First Named Inventor	Egil JELLUM et al
		Art Unit	1645
		Examiner Name	Unassigned
Sheet	5	of	5
		Attorney Docket Number	
		Q90288	

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## NON-PATENT LITERATURE DOCUMENTS

**Examiner Signature** \_\_\_\_\_ **Date Considered** \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.